Varenicline’s Black Box Warning

Varenicline (Chantix) is a nicotine partial agonist that is approved by the FDA for smoking cessation. Since July 1, 2009, the FDA has also required a “black box warning” based on postmarketing reports of adverse neuropsychiatric effects.

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.